References

nefr

Нефрология

Nephrology (Saint-Petersburg)

1561-62742541-9439

Pavlov First Saint-Petersburg State Medical University

10.24884/1561-6274-2018-22-6-77-83

nefr-1631

Research Article

ПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ПО НЕФРОЛОГИИ

PROGRAM ON CONTINUOUS POSTGRADUATE EDUCATION ON NEPHROLOGY

ПОСТТРАНСПЛАНТАЦИОННЫЕ ЛИМФОПРОЛИФЕРАТИВНЫЕ ЗАБОЛЕВАНИЯ У ПАЦИЕНТОВ С ПОЧЕЧНЫМ АЛЛОТРАНСПЛАНТАТОМ

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN PATIENTS WITH KIDNEY ALLOGRAFT

Прокопенко

E. И.

Prokopenko

129110, Россия, Москва, ул. Щепкина, д. 61/2.

Прокопенко Елена Ивановна, д-р мед. наук.

Тел.: (495)6845791.

129110 Russia, Moscow, Shchepkin st., 61/2.

Elena I. Prokopenko MD PhD.

Phone: (495)6845791.

renalnephron@gmail.com

Щербакова

Е. О.

Shcherbakova

129110, Россия, Москва, ул. Щепкина, д. 61/2.

Щербакова Евгения Оттовна, канд. мед. наук.

Тел.: (495)6845791.

129110 Russia, Moscow, Shchepkin st., 61/2.

Evgenia O. Shcherbakova MD PhD.

Phone: (495)6845791.

eottovna@yandex.ru

Кафедра трансплантологии, нефрологии и искусственных органов факультета усовершенствования врачей, Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского.РоссияDepartment of transplantology, nephrology and artificial organs, Postgraduate Medical Faculty, M.F. Vladimirsky Moscow Regional Research Clinical Institute.Russian Federation

2018

23122018

2267783

2018

Прокопенко E.И., Щербакова Е.О.

Prokopenko E., Shcherbakova E.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nephrolog.ru/jour/article/view/1631

Посттрансплантационные лимфопролиферативные заболевания (ПТЛЗ) являются серьезным осложнением после трансплантации почки, негативно влияющим на выживаемость реципиентов и трансплантатов. Важным фактором патогенеза ранних ПТЛЗ является активная инфекция, вызванная вирусом Эпштейна–Барра (ЭБВ), при этом поздние ПТЛЗ нередко бывают ЭБВ-негативными. В диагностике ПТЛЗ важную роль играет использование современных визуализационных методов исследования (компьютерная томография, позитронно-эмиссионная томография), а также морфологическое исследование пораженных органов. В статье рассматриваются классификация ПТЛЗ, факторы риска их развития, особенности патогенеза, подходы к профилактике и лечению.

Post-transplant lymphoproliferative disorders (PTLD) are a serious complication after kidney transplantation, which negatively affects the survival of recipients and transplants. An important factor in the pathogenesis of early PTLD is an active infection caused by the Epstein-Barr virus (EBV), while late PTLD are often EBV-negative. The use of modern imaging research methods (computed tomography, positron emission tomography), as well as morphological study of the affected organs plays an important role in the diagnosis of PTLD. The article discusses the classification of PTLD, risk factors, features of pathogenesis, approaches to prevention and treatment.

посттрансплантационные лимфопролиферативные заболеваниятрансплантация почкииммуносупрессиявирус Эпштейна–Барра

post-transplant lymphoproliferative disorderskidney transplantationimmunosuppressionEpstein–Barr virus

References1

Ватазин АВ, Дутов ВВ, Зулькарнаев АБ и др. Инфекционные осложнения после трансплантации почки. Урология 2013; 3:107–111

Vatazin AV, Dutov VV, Zul'karnaev AB i dr. Infekcionnye oslozhnenija posle transplantacii pochki. Urologija 2013; 3:107–111

Ватазин АВ, Зулькарнаев АБ, Дмитриева НГ и др. Роль системы HLA в отторжении почечного трансплантата. Альманах клинической медицины 2013; 29:79–83

Vatazin AV, Zul'karnaev AB, Dmitrieva NG i dr. Rol'sistemy HLA v ottorzhenii pochechnogo transplantata. Al'manah klinicheskoj mediciny 2013; 29:79–83

Petrara MR, Giunco S, Serraino D et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesisdriven treatment. Cancer Lett 2015; 369(1):37–44. doi: 10.1016/j.canlet.2015.08.007

Starzl TE, Porter KA, Iwatsuki S et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1:583–587

Swerdlow SH. Pathology. In: Dharnidharka VR, Green M, Webber SA, eds. Post-transplant lymphoproliferative disorders. Berlin and Heidelberg, Germany: Springer-Verlag; 2010: 89–104

Dierickx D, Tousseyn Th, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood 2015; 126:2274–2283. doi: 10.1182/blood-2015-05-615872

Fellner MD, Durand KA, Solernou V et al. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders. Rev Argent Microbiol 2016; 48(2):110–118. doi: 10.1016/j.ram.2016.02.006

Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Posttransplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL et al, eds. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 2008:343–349

Krishnamurthy S, Hassan A, Frater JL et al. Pathologic and clinical features of Hodgkin lymphoma–like posttransplant lymphoproliferative disease. Int J Surg Pathol 2010; 18(4):278–285. doi: 10.1177/1066896909338597

Morscio J, Dierickx D, Nijs J et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014; 38(7):875–886. doi: 10.1097/PAS.0000000000000234

Tiede C, Maecker-Kolhoff B, Klein C et al. Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation 2013; 95(3):479–488. doi: 10.1097/TP.0b013e3182762e07

Herreman A, Dierickx D, Morscio J et al. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma 2013; 54(10):2190–2199. doi: 10.3109/10428194.2013.775436

Romero S, Montoro J, Guinot M et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma 2018 Jul 3:1–9. doi: 10.1080/10428194.2018.1474462

Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007; 131(8): 1209–1218. doi: 10.1043/1543-2165(2007)131[1209:TCSOPL]2.0.CO;2

Kobayashi M, Asano N, Fukushima M, Honda T. Three different histological subtypes of Epstein-Barr virus-negative posttransplant lymphoproliferative disorder in a patient withhepatitis C infection. Int J Hematol 2014; 100: 307–311. doi: 10.1007/s12185-014-1599-6

Khan G, Hashim MH. Global burden of deaths from Epstein-Barrvirus attributable malignancies 1990-2010. Infect Agent Cancer 2014; 9:38. doi: 10.1186/1750-9378-9-38

Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86(2):206–209. doi: 10.1002/ajh.21911

Engels EA, Pfeiffer RM, Fraumeni Jr JF et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891–1901

Ibrahim HA, Naresh KN. Posttransplant lymphoproliferative disorders. Adv Hematol 2012; 2012:230173. doi: 10.1155/2012/230173

Smets F, Sokal EM. Prevention and treatment for Epstein-Barr virus infection and related cancers. Recent Results Cancer Res 2014;193:173–190. doi: 10.1007/978-3-642-38965-8_10

Aguayo-Hiraldo P, Arasaratnam R, Rouce RH. Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease. Bol Med Hosp Infant Mex 2016; 73(1):31–40. doi: 10.1016/j.bmhimx.2015.11.007

Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56(1):155–167. doi: 10.1016/j.critrevonc.2005.03.015

United States Organ Transplantation. 2012 Annual Data Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2000–2010. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Am J Transplant 2014; 14(Suppl 1):8–183

Steiner R, Kridel R, Giostra E et al. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. Swiss Med Wkly 2018 Mar 8; 148: w14596. doi: 10.4414/smw.2018.14596

Piselli P, Serraino D, Segoloni GP et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer 2013; 49(2):336–344. doi: 10.1016/j.ejca.2012.09.013

Gwon JG, Kim YH, Han DJ. Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000. Asian J Surg 2018 Oct 13. pii: S1015–9584(18)30481-0. doi: 10.1016/j.asjsur.2018.09.002. [Epub ahead of print]

Rahimzadeh N, Otukesh H, Hoseini R, Riahifard A. Pretransplant Epstein-Barr virus serostatus and incidence of posttransplant lymphoproliferative disorder in pediatric renal transplants. Exp Clin Transplant 2013; 4:299–302. doi: 10.6002/ect.2012.0204

Kalinova L, Indrakova J, Bachleda P. Post-transplant lymphoproliferative disorder. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153(4):251–257

Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4(10):757–768. doi: 10.1038/nrc1452

Petrara MR, Freguja R, Gianesin K et al. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol 2013; 4:311. doi: 10.3389/fmicb.2013.00311

Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007; 7(2):96–101. doi: 10.1016/j.autrev.2007.02.012

Terrin L, Dal Col J, Rampazzo E et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol 2008; 82(20):10175–10187. doi: 10.1128/JVI.00321-08

Giunco S, Celeghin A, Gianesin K et al. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death Dis 2015; 6:e1774. doi: 10.1038/cddis.2015.145

Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 370516. doi: 10.1155/2012/370516

Hong GK, Kumar P, Wang L et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005; 79(22):13984–13992. doi: 10.1128/JVI.79.22.13984-13992.2005

Maksten EF, Vase MØ, Kampmann J et al. Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study. Transplant Int 2016; 29:483–493. doi:10.1111/tri.12744

Khedmat H, Ghamar-Chehreh M E, Amini M et al. Localization of post-transplant lymphoproliferative disorders to the stomach might be associated with favorable outcome: a systematic review. Saudi J Kidney Dis Transpl 2014; 25(2): 353–361

Lake W, Chang JE, Kennedy T et al. A case series of primary central nervous system post-transplant lymphoproliferative disorder: imaging and clinical characteristics. Neurosurgery 2013; 72(6):960–970. doi: 10.1227/NEU.0b013e31828cf619

Obanor SO, Gruttadauria M, Applebaum K et al. Posttransplant lymphoproliferative disorder presenting as testicular lymphoma in a kidney transplant recipient: a case report and review of the literature. Hindawi Case Reports in Nephrology 2018. Article ID 9787093, 6 p. doi: 10.1155/2018/9787093

Thibaud V, Rivalan J, Llamas F et al. Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: A case report. Nephrol Ther 2018 Oct 6. pii: S1769–7255(18)30563-7. doi: 10.1016/j.nephro.2018.07.404

Evens AM, Choquet S, Kroll-Desrosiers AR et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant 2013; 13(6):1512–1522. doi: 10.1111/ajt.12211

Camacho JC, Moreno CC, Harri PA et al. Posttransplantation lymphoproliferative disease: proposed imaging classification. Radiographics 2014; 34:2025–2038. doi: 10.1148/rg.347130130

Li J, Liu Y, Wang Zh et al. Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts. Medicine 2018; 97:17. doi: 10.1097/MD.0000000000010531

Demir E, Karaoglan C, Yegen G et al. Extreme hypercalcemia in a kidney transplant recipient. CEN Case Rep 2018; 7(2): 229–233. doi: 10.1007/s13730-018-0334-1

Sharfuddin A. Imaging evaluation of kidney transplant recipients. Semin Nephrol. 2011; 31: 259–271. doi: 10.1016/j.semnephrol.2011.05.005

Vrachliotis TG, Vaswani KK, Davies EA et al. CT findings in posttransplantation lymphoproliferative disorder of renal transplants. AJR Am J Roentgenol 2000; 175: 183–188. doi: 10.2214/ajr.175.1.1750183

Ginat DT, Purakal A, Pytel P. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma. J Neurooncol 2015; 125:297–305. doi: 10.1007/s11060-015-1903-1

Metser U, Lo G. FDG-PET/CT in abdominal posttransplant lymphoproliferative disease. Br J Radiol 2016; 89:20150844. doi: 10.1259/bjr.20150844

Kitajima K, Sasaki H, Koike J et al. Asymptomatic posttransplant lymphoproliferative disorder diagnosed at one year protocol renal allograft biopsy. Nephrology (Carlton) 2014; 19(Suppl 3):42–44. doi: 10.1111/nep.12246

San-Juan R, Manuel O, Hirsch HH et al. Current preventive strategies and management of Epstein–Barr virusrelated post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect 2015; 21:604. e1–604.e9. doi: 10.1016/j.cmi.2015.02.002

Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 1999; 213: 73–78

Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med 2005; 56:29–44. doi: 10.1146/annurev.med.56.082103.104727

Rabot N, Buchler M, Foucher Y et al. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Steunstichting ESOT 2014; 27:956–965

Ferreira H, Bustorff M, Santos J et al. Post-transplant lymphoproliferative disorder: a single-center experience. Transplant Proc 2015; 47(4):981–984. doi: 10.1016/j.transproceed.2015.03.017

Wowro SJ, Schmitt KRL, Tong G et al. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells. Immunopharmacol. 2016; 30:9–17. doi: 10.1016/j.intimp.2015.11.020

Nieto-Rios JF, Gómez de Los Ríos SM, Serna-Higuita LM et al. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. Colomb Med (Cali) 2016; 47(4):196–202

Gonz´alez-Barca E, Domingo-Domenech E, Capote FJ et al; GEL/TAMO (Grupo Espan˜ ol de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncol´ogico para el Tratamiento y Estudio de los Linfomas). Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007; 92(11):1489–1494. doi: 10.3324/haematol.11360

Choquet S, Oertel S, LeBlond V et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86(8):599–607. doi: 10.1007/s00277-007-0298-2

Trappe R, Oertel S, Leblond V et al; German PTLD Study Group; European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell posttransplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13(2):196–206. doi: 10.1016/S1470-2045(11)70300-X

Gottschalk S, Rooney CM. Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol 2015; 391:427–454. doi: 10.1007/978-3-319-22834-1_15

Dierickx D, Tousseyn T, Sagaert X et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 2013; 54(11):2433–2440. doi: 10.3109/10428194.2013.780655

Ready E, Chernushkin K, Partovi N et al. Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis. Can J Kidney Health Dis 2018; 5:2054358118760831. doi: 10.1177/2054358118760831

Гаврилина ОА, Троицкая ВВ, Звонков ЕЕ и др. Лимфопролиферативное EBV-позитивное заболевание с поражением центральной нервной системы, ассоциированное с иммуносупрессией после органной трансплантации: длительная ремиссия после химиотерапевтического лечения. Тер Архив 2017; 89(7):69–75

Gavrilina OA, Troickaja VV, Zvonkov EE i dr. Limfoproliferativnoe EBV-pozitivnoe zabolevanie s porazheniem central'noj nervnoj sistemy, associirovannoe s immunosupressiej posle organnoj transplantacii: dlitel'naja remissija posle himioterapevticheskogo lechenija. Ter Arhiv 2017; 89(7): 69–75

The authors declare that there are no conflicts of interest present.